Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.64 |
| ▸ | PTPRA | P18433 | 5/20 | 0.64 |
| ▸ | PTPRF | P10586 | 2/20 | 0.64 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7059635 | 0.81 | ERAP2 (0.48) | PTPN1PTPRAPTPRF | |
| SCHEMBL7061206 | 0.80 | PTPN1 (0.66) | PTPN1PTPRAPTPRFPTPN2MEN1 | |
| SCHEMBL7065002 | 0.77 | TACR1 (0.48) | PTPN1MEN1ALDH1A1KMT2A | |
| SCHEMBL6503900 | 0.77 | CTSS (0.52) | PTPN1PTPRA | |
| SCHEMBL6503851 | 0.76 | PTPN1 (0.51) | PTPN1PTPRAPTPRFPTPN2 | |
| SCHEMBL7123456 | 0.75 | PTPN1 (0.83) | PTPN1PTPRAPTPRFPTPN2 | |
| SCHEMBL6491657 | 0.72 | CTSS (0.47) | — | |
| SCHEMBL23933822 | 0.70 | GRIA1 (0.69) | — | |
| SCHEMBL23933818 | 0.70 | GRIA1 (0.69) | — | |
| SCHEMBL19715244 | 0.70 | MMP2 (0.70) | MMP2MMP8MMP1MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885PTPRA 11/4885PTPRF 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.